Liver cancer trial aims to stop return of disease with Pre-Surgery combo
NCT ID NCT07352007
First seen Jan 22, 2026 · Last updated May 08, 2026 · Updated 15 times
Summary
This study tests whether giving a combination of an immunotherapy drug (sintilimab) and targeted radiation before surgery can lower the chance of liver cancer coming back. About 110 adults with resectable liver cancer will be randomly assigned to receive the combination before surgery or to have surgery alone. After surgery, both groups will continue immunotherapy for up to a year to help keep the cancer from returning.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ShandongShandong Cancer Hospital and Institute
Jinan, Shandong, China
Conditions
Explore the condition pages connected to this study.